{
    "info": {
        "nct_id": "NCT02948283",
        "official_title": "A Pilot Feasibility Study of Metformin/Ritonavir Combination Treatment in Patients With Relapsed/Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia",
        "inclusion_criteria": "* All subjects must have the ability to understand and the willingness to sign a written informed consent\n* Life expectancy of > 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nFOR PATIENTS WITH MULTIPLE MYELOMA (MM):\n\n* Diagnosis of multiple myeloma\n* Patients with MM must have measurable disease, defined as one or more of the following:\n\n  * Serum M-protein >= 0.5 g/dL\n  * Urine M-protein >= 200 mg/24 hr\n  * Serum immunoglobulin free light chain (FLC) >= 100 mg/L (10 mg/dL) and abnormal serum immunoglobulin kappa to lambda FLC ratio\n\n    * IgA patients must have serum quantitative immunoglobulin >= 750 mg/dL\n    * Patients with oligosecretory or non-secretory disease must have a documented abnormal free light chain ratio (normal value 0.26 to 1.65) or a value beyond the laboratory calculation range\n* Disease must be refractory or relapsed after >= 3 prior regimens (induction therapy and stem cell transplant +/- maintenance will be considered as one regimen)\n\nFOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL):\n\n* Diagnosis of CLL without the following: Richter's transformation, prolymphocytic leukemia (PLL), small lymphocytic lymphoma (SLL)\n* Measurable disease, defined as one or more of the following:\n\n  * Lymphocytosis >= 5000 in peripheral blood\n  * Measurable lymph nodes > 1.5 cm on palpation and/or computed tomography (CT) scan\n  * Organomegaly by physical exam and/or CT scan\n* Active disease per International Workshop on Chronic Lymphocytic (IWCLL) 2008 criteria, as defined as one of the following:\n\n  * Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia\n  * Massive (i.e., at least 6 cm below the left costal margin) or progressive or symptomatic splenomegaly\n  * Massive nodes (i.e., at least 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy\n  * Progressive lymphocytosis with an increase of more than 50 percent over a two-month period or lymphocyte doubling time (LDT) of less than six months; LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of two weeks over an observation period of two to three months; in patients with initial blood lymphocyte counts of less than 30 x 10^9/L (30,000/L), LDT should not be used as a single parameter to define a treatment indication; in addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infection) should be excluded\n  * Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy\n  * Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs:\n\n    * Unintentional weight loss of 10 percent or more within the previous six months\n    * Significant fatigue (i.e., ECOG performance scale [PS] 2 or worse; inability to work or perform usual activities)\n    * Fevers higher than 100.5 degrees Fahrenheit (F) or 38.0 degrees Celsius (C) for two or more weeks without other evidence of infection\n    * Night sweats for more than one month without evidence of infection\n* Received at least 2 prior therapies (regimens) for CLL\n* In the opinion of the investigator do not require rapid cytoreduction due to bulky disease (e.g. painful lymphadenopathy or organomegaly, or impending end-organ dysfunction\n* Absolute neutrophil count (ANC) >= 1,000/mm^3\n* Platelets >= 50,000/mm^3\n* Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) =< 3 x ULN\n* Total bilirubin =< 1.5 x ULN; unless presence of Gilbert's syndrome, liver involvement by CLL or MM, or stable chronic liver disease per investigator's assessment\n* Creatinine clearance of >= 45 mL/min per 24 hour urine collection or the Cockcroft-Gault formula\n* Woman of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Corrected QT interval (QTc) =< 480 msec per Fridericia's formula AND PR interval =< 200 msec (using 12-lead electrocardiography [EKG])\n* Agreement by woman of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for three months following duration of study participation\n\n  * A woman of childbearing potential is defined as a sexually mature woman who:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy; or\n    * Has not been naturally postmenopausal for at least 24 consecutive months\n\nFOR PATIENTS WITH MM OR CLL:\n\n- At least 2 weeks from prior therapy to time of start of treatment; prior therapy includes steroids (except for =< 10 mg daily prednisone or equivalent which is permitted during the study)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Current or planned use of other investigational agents, or concurrent biological, chemotherapy, or radiation therapy during the study treatment period\n* Use of a protease inhibitor for any indication within three months prior to start of study treatment\n* Current or planned use of prohibited meds\n* Liver disease, except Gilbert's syndrome, liver involvement by CLL or MM, or stable chronic liver disease per investigator's assessment\n* Current pancreatitis\n* History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to metformin, ritonavir or any of their ingredients\n* Non-hematologic malignancy within the past 3 years aside from the following exceptions:\n\n  * Adequately treated basal cell or squamous cell skin cancer\n  * Carcinoma in situ of the cervix\n  * Prostate cancer < Gleason grade 6 with a stable prostate-specific antigen test (PSA)\n  * Successfully treated in situ carcinoma of the breast\n* Clinically significant cardiac disease, including:\n\n  * >= Grade 2 myocardial infarction within 6 months prior to day 1 of protocol therapy\n  * Unstable or uncontrolled disease condition relating to or affecting cardiac function (e.g. unstable angina, congestive heart failure, New York Heart Association Class III-IV) within 6 months prior to day 1 of protocol therapy\n  * >= Grade 2 uncontrolled cardiac arrhythmia\n* Clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or the patient's ability to give informed consent\n* Women who are currently or planning to breastfeed during protocol treatment\n* Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, uncontrolled intercurrent illness etc.\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) =< 3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 3 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs:",
            "criterions": [
                {
                    "exact_snippets": "Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs",
                    "criterion": "constitutional symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with MM must have measurable disease, defined as one or more of the following:",
            "criterions": [
                {
                    "exact_snippets": "Patients with MM must have measurable disease",
                    "criterion": "measurable disease in multiple myeloma (MM)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 50,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 50,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease must be refractory or relapsed after >= 3 prior regimens (induction therapy and stem cell transplant +/- maintenance will be considered as one regimen)",
            "criterions": [
                {
                    "exact_snippets": "Disease must be refractory or relapsed",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "refractory",
                                "relapsed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": ">= 3 prior regimens (induction therapy and stem cell transplant +/- maintenance will be considered as one regimen)",
                    "criterion": "number of prior regimens",
                    "requirements": [
                        {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QT interval (QTc) =< 480 msec per Fridericia's formula AND PR interval =< 200 msec (using 12-lead electrocardiography [EKG])",
            "criterions": [
                {
                    "exact_snippets": "Corrected QT interval (QTc) =< 480 msec per Fridericia's formula",
                    "criterion": "corrected QT interval (QTc)",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 480,
                                "unit": "msec"
                            }
                        },
                        {
                            "requirement_type": "correction_formula",
                            "expected_value": "Fridericia's formula"
                        }
                    ]
                },
                {
                    "exact_snippets": "PR interval =< 200 msec (using 12-lead electrocardiography [EKG])",
                    "criterion": "PR interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 200,
                                "unit": "msec"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": "12-lead electrocardiography (EKG)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progressive lymphocytosis with an increase of more than 50 percent over a two-month period or lymphocyte doubling time (LDT) of less than six months; LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of two weeks over an observation period of two to three months; in patients with initial blood lymphocyte counts of less than 30 x 10^9/L (30,000/L), LDT should not be used as a single parameter to define a treatment indication; in addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infection) should be excluded",
            "criterions": [
                {
                    "exact_snippets": "Progressive lymphocytosis with an increase of more than 50 percent over a two-month period",
                    "criterion": "lymphocytosis",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "increase",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "percent"
                            }
                        },
                        {
                            "requirement_type": "time_period",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "lymphocyte doubling time (LDT) of less than six months",
                    "criterion": "lymphocyte doubling time (LDT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in patients with initial blood lymphocyte counts of less than 30 x 10^9/L (30,000/L), LDT should not be used as a single parameter to define a treatment indication",
                    "criterion": "initial blood lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "LDT as single parameter for treatment indication",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infection) should be excluded",
                    "criterion": "factors contributing to lymphocytosis or lymphadenopathy other than CLL",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lymphocytosis >= 5000 in peripheral blood",
            "criterions": [
                {
                    "exact_snippets": "Lymphocytosis >= 5000 in peripheral blood",
                    "criterion": "lymphocytosis in peripheral blood",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5000,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urine M-protein >= 200 mg/24 hr",
            "criterions": [
                {
                    "exact_snippets": "Urine M-protein >= 200 mg/24 hr",
                    "criterion": "urine M-protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 hr"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of > 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of > 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fevers higher than 100.5 degrees Fahrenheit (F) or 38.0 degrees Celsius (C) for two or more weeks without other evidence of infection",
            "criterions": [
                {
                    "exact_snippets": "Fevers higher than 100.5 degrees Fahrenheit (F) or 38.0 degrees Celsius (C) for two or more weeks",
                    "criterion": "fever",
                    "requirements": [
                        {
                            "requirement_type": "temperature",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 100.5,
                                        "unit": "degrees Fahrenheit"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 38.0,
                                        "unit": "degrees Celsius"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without other evidence of infection",
                    "criterion": "evidence of infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease, defined as one or more of the following:",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A woman of childbearing potential is defined as a sexually mature woman who:",
            "criterions": [
                {
                    "exact_snippets": "woman of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sexually mature",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All subjects must have the ability to understand and the willingness to sign a written informed consent",
            "criterions": [
                {
                    "exact_snippets": "ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement by woman of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for three months following duration of study participation",
            "criterions": [
                {
                    "exact_snippets": "Agreement by woman of childbearing potential ... to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for three months following duration of study participation",
                    "criterion": "contraception use by women of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "hormonal",
                                "barrier method of birth control",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to study entry and for three months following duration of study participation"
                        }
                    ]
                },
                {
                    "exact_snippets": "Agreement by ... sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for three months following duration of study participation",
                    "criterion": "contraception use by sexually active males",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "hormonal",
                                "barrier method of birth control",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to study entry and for three months following duration of study participation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL):",
            "criterions": [
                {
                    "exact_snippets": "FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)",
                    "criterion": "chronic lymphocytic leukemia (CLL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of CLL without the following: Richter's transformation, prolymphocytic leukemia (PLL), small lymphocytic lymphoma (SLL)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of CLL",
                    "criterion": "chronic lymphocytic leukemia (CLL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without the following: Richter's transformation",
                    "criterion": "Richter's transformation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "without the following: ... prolymphocytic leukemia (PLL)",
                    "criterion": "prolymphocytic leukemia (PLL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "without the following: ... small lymphocytic lymphoma (SLL)",
                    "criterion": "small lymphocytic lymphoma (SLL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with oligosecretory or non-secretory disease must have a documented abnormal free light chain ratio (normal value 0.26 to 1.65) or a value beyond the laboratory calculation range",
            "criterions": [
                {
                    "exact_snippets": "Patients with oligosecretory or non-secretory disease",
                    "criterion": "oligosecretory or non-secretory disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a documented abnormal free light chain ratio (normal value 0.26 to 1.65) or a value beyond the laboratory calculation range",
                    "criterion": "free light chain ratio",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 0.26,
                                        "unit": ""
                                    },
                                    {
                                        "operator": ">",
                                        "value": 1.65,
                                        "unit": ""
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "beyond laboratory calculation range",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum M-protein >= 0.5 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Serum M-protein >= 0.5 g/dL",
                    "criterion": "serum M-protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unintentional weight loss of 10 percent or more within the previous six months",
            "criterions": [
                {
                    "exact_snippets": "Unintentional weight loss of 10 percent or more within the previous six months",
                    "criterion": "unintentional weight loss",
                    "requirements": [
                        {
                            "requirement_type": "amount",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "percent"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within the previous six months"
                        }
                    ]
                }
            ]
        },
        {
            "line": "- At least 2 weeks from prior therapy to time of start of treatment; prior therapy includes steroids (except for =< 10 mg daily prednisone or equivalent which is permitted during the study)",
            "criterions": [
                {
                    "exact_snippets": "At least 2 weeks from prior therapy to time of start of treatment",
                    "criterion": "interval since prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior therapy includes steroids (except for =< 10 mg daily prednisone or equivalent which is permitted during the study)",
                    "criterion": "steroid use",
                    "requirements": [
                        {
                            "requirement_type": "maximum daily dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "steroid type",
                            "expected_value": [
                                "prednisone",
                                "prednisone equivalent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active disease per International Workshop on Chronic Lymphocytic (IWCLL) 2008 criteria, as defined as one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Active disease per International Workshop on Chronic Lymphocytic (IWCLL) 2008 criteria",
                    "criterion": "chronic lymphocytic leukemia (CLL) disease activity",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active per IWCLL 2008 criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1,000/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Massive nodes (i.e., at least 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy",
            "criterions": [
                {
                    "exact_snippets": "Massive nodes (i.e., at least 10 cm in longest diameter)",
                    "criterion": "lymph node size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive ... lymphadenopathy",
                    "criterion": "lymphadenopathy progression",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic lymphadenopathy",
                    "criterion": "lymphadenopathy symptoms",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received at least 2 prior therapies (regimens) for CLL",
            "criterions": [
                {
                    "exact_snippets": "Received at least 2 prior therapies (regimens) for CLL",
                    "criterion": "prior therapies for CLL",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant fatigue (i.e., ECOG performance scale [PS] 2 or worse; inability to work or perform usual activities)",
            "criterions": [
                {
                    "exact_snippets": "Significant fatigue",
                    "criterion": "fatigue",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "ECOG performance scale [PS] 2 or worse",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to work or perform usual activities",
                    "criterion": "ability to work or perform usual activities",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "FOR PATIENTS WITH MM OR CLL:",
            "criterions": [
                {
                    "exact_snippets": "FOR PATIENTS WITH MM OR CLL",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "multiple myeloma",
                                "chronic lymphocytic leukemia"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia",
            "criterions": [
                {
                    "exact_snippets": "Evidence of progressive marrow failure",
                    "criterion": "progressive marrow failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "development of, or worsening of, anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "development or worsening",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "development of, or worsening of, ... thrombocytopenia",
                    "criterion": "thrombocytopenia",
                    "requirements": [
                        {
                            "requirement_type": "development or worsening",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable lymph nodes > 1.5 cm on palpation and/or computed tomography (CT) scan",
            "criterions": [
                {
                    "exact_snippets": "Measurable lymph nodes > 1.5 cm on palpation and/or computed tomography (CT) scan",
                    "criterion": "lymph nodes",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "palpation",
                                "computed tomography (CT) scan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Massive (i.e., at least 6 cm below the left costal margin) or progressive or symptomatic splenomegaly",
            "criterions": [
                {
                    "exact_snippets": "Massive (i.e., at least 6 cm below the left costal margin) ... splenomegaly",
                    "criterion": "splenomegaly",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "cm below the left costal margin"
                            }
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "massive"
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive ... splenomegaly",
                    "criterion": "splenomegaly",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic splenomegaly",
                    "criterion": "splenomegaly",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum immunoglobulin free light chain (FLC) >= 100 mg/L (10 mg/dL) and abnormal serum immunoglobulin kappa to lambda FLC ratio",
            "criterions": [
                {
                    "exact_snippets": "Serum immunoglobulin free light chain (FLC) >= 100 mg/L (10 mg/dL)",
                    "criterion": "serum immunoglobulin free light chain (FLC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mg/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormal serum immunoglobulin kappa to lambda FLC ratio",
                    "criterion": "serum immunoglobulin kappa to lambda FLC ratio",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "abnormal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance of >= 45 mL/min per 24 hour urine collection or the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance of >= 45 mL/min per 24 hour urine collection or the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "24 hour urine collection",
                                "Cockcroft-Gault formula"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In the opinion of the investigator do not require rapid cytoreduction due to bulky disease (e.g. painful lymphadenopathy or organomegaly, or impending end-organ dysfunction",
            "criterions": [
                {
                    "exact_snippets": "do not require rapid cytoreduction due to bulky disease",
                    "criterion": "requirement for rapid cytoreduction",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "bulky disease (e.g. painful lymphadenopathy or organomegaly, or impending end-organ dysfunction",
                    "criterion": "bulky disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "painful lymphadenopathy",
                    "criterion": "painful lymphadenopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "organomegaly",
                    "criterion": "organomegaly",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "impending end-organ dysfunction",
                    "criterion": "impending end-organ dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x upper limit of normal (ULN)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of multiple myeloma",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of multiple myeloma",
                    "criterion": "multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* IgA patients must have serum quantitative immunoglobulin >= 750 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "IgA patients must have serum quantitative immunoglobulin >= 750 mg/dL",
                    "criterion": "serum quantitative immunoglobulin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 750,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x ULN; unless presence of Gilbert's syndrome, liver involvement by CLL or MM, or stable chronic liver disease per investigator's assessment",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x ULN; unless presence of Gilbert's syndrome, liver involvement by CLL or MM, or stable chronic liver disease per investigator's assessment",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "presence of Gilbert's syndrome",
                                "liver involvement by CLL or MM",
                                "stable chronic liver disease per investigator's assessment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has not undergone a hysterectomy or bilateral oophorectomy; or",
            "criterions": [
                {
                    "exact_snippets": "Has not undergone a hysterectomy",
                    "criterion": "hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Has not undergone ... bilateral oophorectomy",
                    "criterion": "bilateral oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Organomegaly by physical exam and/or CT scan",
            "criterions": [
                {
                    "exact_snippets": "Organomegaly by physical exam and/or CT scan",
                    "criterion": "organomegaly",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "physical exam",
                                "CT scan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy",
            "criterions": [
                {
                    "exact_snippets": "Autoimmune anemia and/or thrombocytopenia",
                    "criterion": "autoimmune anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Autoimmune anemia and/or thrombocytopenia",
                    "criterion": "autoimmune thrombocytopenia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "poorly responsive to corticosteroids or other standard therapy",
                    "criterion": "autoimmune anemia or thrombocytopenia responsiveness to corticosteroids or other standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "responsiveness",
                            "expected_value": "poorly responsive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Night sweats for more than one month without evidence of infection",
            "criterions": [
                {
                    "exact_snippets": "Night sweats for more than one month",
                    "criterion": "night sweats",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "FOR PATIENTS WITH MULTIPLE MYELOMA (MM):",
            "criterions": [
                {
                    "exact_snippets": "FOR PATIENTS WITH MULTIPLE MYELOMA (MM)",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has not been naturally postmenopausal for at least 24 consecutive months",
            "criterions": [
                {
                    "exact_snippets": "Has not been naturally postmenopausal for at least 24 consecutive months",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "postmenopausal duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Woman of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
            "criterions": [
                {
                    "exact_snippets": "Woman of childbearing potential (WOCBP)",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine or serum pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Current pancreatitis",
            "criterions": [
                {
                    "exact_snippets": "Current pancreatitis",
                    "criterion": "pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, uncontrolled intercurrent illness etc.",
            "criterions": [
                {
                    "exact_snippets": "infection/inflammation",
                    "criterion": "infection or inflammation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intestinal obstruction",
                    "criterion": "intestinal obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to swallow medication",
                    "criterion": "ability to swallow medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "social/ psychological issues",
                    "criterion": "social or psychological issues",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled intercurrent illness",
                    "criterion": "uncontrolled intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or the patient's ability to give informed consent",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant medical disease or condition",
                    "criterion": "clinically significant medical disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the investigator's opinion, may interfere with protocol adherence",
                    "criterion": "potential to interfere with protocol adherence",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the investigator's opinion, may interfere with ... the patient's ability to give informed consent",
                    "criterion": "potential to interfere with ability to give informed consent",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Carcinoma in situ of the cervix",
            "criterions": [
                {
                    "exact_snippets": "Carcinoma in situ of the cervix",
                    "criterion": "carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* >= Grade 2 uncontrolled cardiac arrhythmia",
            "criterions": [
                {
                    "exact_snippets": ">= Grade 2 uncontrolled cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of a protease inhibitor for any indication within three months prior to start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Use of a protease inhibitor for any indication within three months prior to start of study treatment",
                    "criterion": "protease inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to start of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* >= Grade 2 myocardial infarction within 6 months prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": ">= Grade 2 myocardial infarction within 6 months prior to day 1 of protocol therapy",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated basal cell or squamous cell skin cancer",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated basal cell or squamous cell skin cancer",
                    "criterion": "basal cell or squamous cell skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-hematologic malignancy within the past 3 years aside from the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Non-hematologic malignancy within the past 3 years",
                    "criterion": "non-hematologic malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are currently or planning to breastfeed during protocol treatment",
            "criterions": [
                {
                    "exact_snippets": "Women who are currently ... breastfeed during protocol treatment",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "current breastfeeding",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... planning to breastfeed during protocol treatment",
                    "criterion": "breastfeeding intention during protocol treatment",
                    "requirements": [
                        {
                            "requirement_type": "intention to breastfeed during protocol treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to metformin, ritonavir or any of their ingredients",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to metformin, ritonavir or any of their ingredients",
                    "criterion": "allergic reactions or hypersensitivity to compounds similar to metformin, ritonavir, or their ingredients",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "attribution",
                            "expected_value": "compounds of similar chemical or biologic composition to metformin, ritonavir or any of their ingredients"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or planned use of prohibited meds",
            "criterions": [
                {
                    "exact_snippets": "Current or planned use of prohibited meds",
                    "criterion": "use of prohibited medications",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "planned use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiac disease, including:",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator's opinion of participant's compliance",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": "participant is able to comply"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Liver disease, except Gilbert's syndrome, liver involvement by CLL or MM, or stable chronic liver disease per investigator's assessment",
            "criterions": [
                {
                    "exact_snippets": "Liver disease, except Gilbert's syndrome, liver involvement by CLL or MM, or stable chronic liver disease per investigator's assessment",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "Gilbert's syndrome",
                                "liver involvement by CLL or MM",
                                "stable chronic liver disease per investigator's assessment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or planned use of other investigational agents, or concurrent biological, chemotherapy, or radiation therapy during the study treatment period",
            "criterions": [
                {
                    "exact_snippets": "Current or planned use of other investigational agents",
                    "criterion": "use of other investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent biological ... therapy during the study treatment period",
                    "criterion": "concurrent biological therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent ... chemotherapy ... during the study treatment period",
                    "criterion": "concurrent chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent ... radiation therapy during the study treatment period",
                    "criterion": "concurrent radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Successfully treated in situ carcinoma of the breast",
            "criterions": [
                {
                    "exact_snippets": "Successfully treated in situ carcinoma of the breast",
                    "criterion": "in situ carcinoma of the breast",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "successfully treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate cancer < Gleason grade 6 with a stable prostate-specific antigen test (PSA)",
            "criterions": [
                {
                    "exact_snippets": "Prostate cancer < Gleason grade 6",
                    "criterion": "prostate cancer Gleason grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stable prostate-specific antigen test (PSA)",
                    "criterion": "prostate-specific antigen test (PSA)",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable or uncontrolled disease condition relating to or affecting cardiac function (e.g. unstable angina, congestive heart failure, New York Heart Association Class III-IV) within 6 months prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Unstable or uncontrolled disease condition relating to or affecting cardiac function",
                    "criterion": "cardiac disease condition",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class III-IV",
                    "criterion": "New York Heart Association class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 6 months prior to day 1 of protocol therapy",
                    "criterion": "time since cardiac event",
                    "requirements": [
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}